Nothing Special   »   [go: up one dir, main page]

ATE481968T1 - Verfahren zur hemmung von tumormetastasierung - Google Patents

Verfahren zur hemmung von tumormetastasierung

Info

Publication number
ATE481968T1
ATE481968T1 AT08162593T AT08162593T ATE481968T1 AT E481968 T1 ATE481968 T1 AT E481968T1 AT 08162593 T AT08162593 T AT 08162593T AT 08162593 T AT08162593 T AT 08162593T AT E481968 T1 ATE481968 T1 AT E481968T1
Authority
AT
Austria
Prior art keywords
tumor metastasis
inhibiting tumor
tumor cell
inhibit tumor
metastasis
Prior art date
Application number
AT08162593T
Other languages
English (en)
Inventor
Masako Nozaki
Original Assignee
Inflammation Res Ct Company Lt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflammation Res Ct Company Lt filed Critical Inflammation Res Ct Company Lt
Application granted granted Critical
Publication of ATE481968T1 publication Critical patent/ATE481968T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT08162593T 2004-07-14 2005-07-14 Verfahren zur hemmung von tumormetastasierung ATE481968T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58750704P 2004-07-14 2004-07-14

Publications (1)

Publication Number Publication Date
ATE481968T1 true ATE481968T1 (de) 2010-10-15

Family

ID=35907711

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08162593T ATE481968T1 (de) 2004-07-14 2005-07-14 Verfahren zur hemmung von tumormetastasierung

Country Status (10)

Country Link
US (3) US20080206203A1 (de)
EP (2) EP1765333A4 (de)
JP (1) JP3983272B2 (de)
KR (1) KR101213926B1 (de)
CN (2) CN101022796B (de)
AT (1) ATE481968T1 (de)
BR (1) BRPI0513351A (de)
DE (1) DE602005023797D1 (de)
HK (2) HK1108118A1 (de)
WO (1) WO2006019874A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775836B2 (en) * 2013-04-22 2017-10-03 Tochigi Institute Of Clinical Pathology Antitumor agent
TWI626046B (zh) * 2015-10-06 2018-06-11 高雄醫學大學 用於預防或治療肺癌的醫藥組合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4528060A (en) 1982-07-08 1985-07-09 Hercules Incorporated Apparatus for winding of filamentary composites
US4720505A (en) * 1983-06-27 1988-01-19 Merck Frosst Canada, Inc. Leukotriene antagonists
CA1261835A (en) * 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
JPS63258879A (ja) 1987-04-16 1988-10-26 Mitsubishi Kasei Corp ビニルチアゾ−ル誘導体およびそれを有効成分とするロイコトリエン拮抗剤
JPS63258854A (ja) 1987-04-16 1988-10-26 Mitsubishi Kasei Corp カルボキシスチレン誘導体およびそれを有効成分とする薬剤
US4985585A (en) 1988-03-07 1991-01-15 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process for their preparations
JPH02169583A (ja) 1988-12-22 1990-06-29 Mitsubishi Kasei Corp ビニルチアゾール誘導体およびそれを有効成分とする薬剤
US5079261A (en) 1989-04-28 1992-01-07 Brigham And Women's Hospital Use of lipoxin a4 and its derivatives as antagonists for slow-reacting substances of anaphylaxis
JP2600644B2 (ja) 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
GB9119001D0 (en) 1991-09-05 1991-10-23 Ici Plc Pharmaceutical agents
US5428060A (en) * 1992-08-27 1995-06-27 Merck Frosst Canada, Inc. Heteroarylnaphthalene lactones as inhibitors of leukotriene biosynthesis
JPH06116163A (ja) * 1992-10-05 1994-04-26 Toagosei Chem Ind Co Ltd 腫瘍抑制剤
DE4424714A1 (de) * 1994-07-13 1996-01-18 Boehringer Ingelheim Kg Neue chemische Verbindung, ihre Herstellung und ihre Verwendung als Arnzneistoff
US5527827A (en) * 1994-10-27 1996-06-18 Merck Frosst Canada, Inc. Bisarylcarbinol cinnamic acids as inhibitors of leukotriene biosynthesis
US5552437A (en) * 1994-10-27 1996-09-03 Merck Frosst Canada, Inc. Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
DE69625813T2 (de) 1995-06-12 2003-09-04 Ono Pharmaceutical Co. Ltd., Osaka Pranlukast enthaltende granula, verfahren zur herstellung der granula und verfahren zur verminderung des zusammenbackens von pranlukast
GB9525261D0 (en) * 1995-12-11 1996-02-07 Bayer Ag Carbamic acid derivatives
US6207654B1 (en) * 1996-05-03 2001-03-27 Bashir Zikria Capillary membrane stabilization and reduction of inflammation during the course of chemotherapy or antiviral treatment through the use of biodegradable macromolecules and interleukin-2
US5911776A (en) 1996-12-18 1999-06-15 Unisys Corporation Automatic format conversion system and publishing methodology for multi-user network
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6355624B1 (en) * 1997-02-05 2002-03-12 University Wales College Of Medicine Measurement of plasma volume
ES2176877T3 (es) 1997-09-26 2002-12-01 Kowa Co Derivados de tetrazol como antagonistas de ltd4 y h1.
WO1999021007A1 (en) 1997-10-23 1999-04-29 Pharmaprint, Inc. Pharmaceutical grade echinacea
DE69927582D1 (de) 1998-05-15 2006-02-16 Univ Vermont Burlington Neue analoga von 16-hydroxyeicosatetraensäure
DE19834713A1 (de) * 1998-07-31 2000-02-03 Boehringer Ingelheim Pharma Neue Phenylethylaminderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU6391199A (en) * 1998-10-09 2000-05-01 Schering Corporation Composition and method for treating allergic diseases
US6221880B1 (en) 1998-10-09 2001-04-24 Schering Corporation Composition and method for treating allergic diseases
US6194432B1 (en) 1998-10-13 2001-02-27 Fred D. Sheftell Prevention and treatment of migraine, cluster and other recurrent headaches using leukotriene antagonist drugs
AUPP910699A0 (en) * 1999-03-10 1999-04-01 Pharmalink International Limited Inhibitor of lipoxygenase pathways
AU779532B2 (en) * 1999-07-21 2005-01-27 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation
KR100381834B1 (ko) * 2000-05-20 2003-04-26 이상득 용출성이 개선된 프란루카스트 고체분산체 조성물 및 그제조 방법
DE10052658A1 (de) * 2000-10-24 2002-05-02 Boehringer Ingelheim Pharma Neue Pyranosidderivate
DE10052333A1 (de) * 2000-10-24 2002-05-02 Boehringer Ingelheim Pharma Neue Sulfooxybenzamide
US7148248B2 (en) * 2002-11-29 2006-12-12 Masako Nozaki Method of treating or inhibiting the development of brain inflammation and sepsis
EP1424101A3 (de) * 2002-11-29 2004-08-18 NOZAKI, Masako Verwendung eines Leukotrien- C4/ D4 -rezeptorantagonisten zur Herstellung eines Medikamentes zur Behandlung oder Vorbeugung von Gehirnentzündung und -sepsis

Also Published As

Publication number Publication date
HK1174533A1 (en) 2013-06-14
CN101022796A (zh) 2007-08-22
EP1765333A1 (de) 2007-03-28
KR20070051855A (ko) 2007-05-18
DE602005023797D1 (de) 2010-11-04
US20190060278A1 (en) 2019-02-28
EP1997491B1 (de) 2010-09-22
JP3983272B2 (ja) 2007-09-26
HK1108118A1 (en) 2008-05-02
CN101022796B (zh) 2013-02-27
KR101213926B1 (ko) 2012-12-18
JP2007514002A (ja) 2007-05-31
US20170014384A1 (en) 2017-01-19
US20080206203A1 (en) 2008-08-28
WO2006019874A1 (en) 2006-02-23
EP1997491A1 (de) 2008-12-03
CN102847155A (zh) 2013-01-02
CN102847155B (zh) 2014-04-16
EP1765333A4 (de) 2008-06-18
BRPI0513351A (pt) 2008-05-06

Similar Documents

Publication Publication Date Title
BRPI0507891A (pt) modulação dos processos inflamatório e metastático
WO2009073201A3 (en) Alternate labeling strategies for single molecule sequencing
DE602004030615D1 (de) Lateralfluss-testvorrichtungen auf membranbasis unter verwendung von phosphoreszenznachweises
ATE395336T1 (de) Chinolinderivate zur verwendung als inhibitoren von mycobakterien
RS52931B (en) VIRAL POLYMERASE INHIBITORS
ATE556457T1 (de) Verfahren zum aktivieren von bornitrid
GB0617429D0 (en) Markers of renal transplant rejection and renal damage
TW200710652A (en) Method and system for NAND-flash identification without reading device ID table
ATE368651T1 (de) Pyridazinon-derivate als gsk-3beta-hemmer
DE602006005396D1 (de) Dachpappezusammensetzung
IS7992A (is) Dýralaus frumuræktunar aðferð
WO2007035864A3 (en) Electrophoresis standards, methods and kits
ATE315585T1 (de) Multispezifisches reagenz zur selektiven stimulierung von zelloberflächenrezeptoren
ATE498134T1 (de) Nachweis von staphylococcus
ATE376833T1 (de) Chinazolinon-derivate als vanilloid-antagonisten
DE602006019618D1 (de) Technik zur kultivierung einer mesenchymalen stammzelle unter verwendung von laminin-5
DE60304138D1 (de) Verfahren zur Bestimmung des Widerstandsindex, als Funktion der Wassersättigung, von bestimmten Gesteinsproben mit komplexer Porosität
ATE481968T1 (de) Verfahren zur hemmung von tumormetastasierung
ATE388941T1 (de) Neue pyrimidin-4,6-dicarbons urediamide zur selektiven inhibierung von kollagenasen
ATE424203T1 (de) Verwendung von inhibitoren des na+/h+ austauschers, subtyp 5 (nhe5) zur gedächtnisverbesserung
NO20063513L (no) Innesluttet biocid
DE602006012938D1 (de) Neue 6-pyridylphenanthridine
DE112007003222A5 (de) Prognostische Marker für die Klassifizierung von kolorektalen Karzinomen basierend auf Expressionsprofilen von biologischen Proben
EA200970074A1 (ru) Химический способ создания давления
ATE532876T1 (de) Substrate zur bestimmung von tafi(a)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties